TeraImmune Extends CRADA for Development of Treg Expansion for Clinical Use
January 04, 2023 08:00 ET
|
TeraImmune, Inc.
GERMANTOWN, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on the discovery and development of novel regulatory T-cell-(Treg)-based cell therapies for...
TeraImmune Presented Research on TREGable™ Technology at HCA Asia 2022
November 18, 2022 08:00 ET
|
TeraImmune, Inc.
GERMANTOWN, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on the discovery and development of novel Treg-based cell therapies for autoimmune diseases,...
TeraImmune Receives FDA IND Clearance to Initiate Phase 1/2a Clinical Trial of TI-168 for Treatment of Hemophilia A with Refractory Inhibitors
October 11, 2022 08:00 ET
|
TeraImmune, Inc.
GERMANTOWN, Md., Oct. 11, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases,...